N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide

Request For Quotation
N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide Suppliers list
Company Name: Shanghai Beckham Medical Technology Co., Ltd  
Tel: 13816613772
Email: huahero21@sina.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Tianjin Kailiqi Biotechnology Co., Ltd.  
Tel: 15076683720
Email: klq@cw-bio.com
Company Name: MQ (shanghai) Pharmaceuticals Co., Ltd.  
Tel: 13761635123
Email: sales@linyuepharm.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com

N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide manufacturers

  • MKI-1
  • MKI-1 pictures
  • $61.00
  • 2026-07-14
  • CAS:1190277-80-5
  • Purity: 99.81%
  • Supply Ability: 10g
N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide Basic information
Product Name:N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide
Synonyms:N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide;MKI-1;Benzamide, N-1H-benzimidazol-2-yl-3-(1H-pyrrol-1-yl)-;MKI-1/MASTL Kinase Inhibitor-1;N-(1H-Benzo[d]imidazol-2-yl)-3-(1H-pyrrol-1-yl)benzamide;MKI-1, 10 mM in DMSO;N-1H-Benzimidazol-2-yl-3-(1H-pyrrol-1-yl)benzamide
CAS:1190277-80-5
MF:C18H14N4O
MW:302.33
EINECS:
Product Categories:
Mol File:1190277-80-5.mol
N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide Structure
N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide Chemical Properties
density 1.31±0.1 g/cm3(Predicted)
pka10.56±0.10(Predicted)
form Solid
color Off-white to light yellow
Safety Information
MSDS Information
N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide Usage And Synthesis
UsesMKI-1, an inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 of 9.9 μM, exerts antitumor and radiosensitizer activities through PP2A activation in breast cancer[1].
in vivo

MKI-1 (50 mg/kg, ip, twice a week) reduces tumor growth and enhances the radiosensitivity of BT549 xenograft model in response to 6 Gy irradiation compared with the control group, with no notable changes in body weight, suggesting the absence of gross toxicity in the treated mice[1].

Animal Model:Five-week-old female BALB/c nude mice (BT549 cells)[1].
Dosage:50 mg/kg.
Administration:Twice per week by intraperitoneal (i.p.) injection.
Result:Reduced tumor growth.
References[1] Ah-Young Kim, et al. MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast cancer. Front Oncol. 2020 Sep 29;10:571601. DOI:10.3389/fonc.2020.571601
N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide Preparation Products And Raw materials
Tag:N-(1H-benzimidazol-2-yl)-3-pyrrol-1-ylbenzamide(1190277-80-5) Related Product Information
N-(3-Cyano-4,5,6,7-tetrahydro-2-benzothienyl)-3-phenylpropanamide Anti-Aging Compound Library Anti-cancer compound library 2-Oxazolidinone, 3-[1-amino-6-[[4-(1-amino-1-ethylpropyl)-2-pyridinyl]amino]-2,7-naphthyridin-3-yl]- N6-[4-(3-Amino-3-pentyl)-2-pyridyl]-3-(1-methyl-1H-1,2,3-triazol-5-yl)-2,7-naphthyridine-1,6-diamine MASTL-IN-3